Data / Drug companies / Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited: 393 products in the FDA NDC directory, labeler code 55111
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Dr. Reddy's Laboratories Limited (labeler code 55111) lists 393 products in the FDA National Drug Code Directory, covering 75 finished drugs by generic name. By type: 196 prescription drugs, 164 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 20, 2025.
The request: Watch Dr. Reddy's Laboratories Limited (FDA labeler code 55111): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55111
- Products in commercial distribution
- 393
- Packages
- 1,057
- Finished drugs by generic name
- 75
- Prescription products
- 196
- Over the counter products
- 18
- Controlled substance products
- Schedule IV 4, Schedule V 1
- Flagged as original packager
- 209 of 209 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- October 9, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 214 | 54.5% |
| Bulk ingredients | 158 | 40.2% |
| Drugs for further processing | 20 | 5.1% |
| Bulk ingredients for compounding | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 196 | 49.9% |
| Bulk ingredients | 164 | 41.7% |
| Over the counter drugs | 18 | 4.6% |
| Drugs for further processing | 15 | 3.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 158 | 40.2% |
| Tablet | 70 | 17.8% |
| Tablet, film coated | 37 | 9.4% |
| Capsule | 30 | 7.6% |
| Tablet, extended release | 20 | 5.1% |
| Capsule, delayed release | 15 | 3.8% |
| Tablet, film coated, extended release | 11 | 2.8% |
| Tablet, coated | 10 | 2.5% |
| Tablet, delayed release | 8 | 2% |
| Tablet, orally disintegrating | 6 | 1.5% |
| Injection | 6 | 1.5% |
| Tablet, chewable | 4 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Donepezil hydrochloride | 55111-302 | Tablet, film coated | Generic drugs (ANDA) | August 20, 2025 |
| Ibuprofen | 55111-684 | Tablet | Drugs for further processing | December 10, 2024 |
| Ibuprofen | 55111-683 | Tablet | Drugs for further processing | December 10, 2024 |
| Ibuprofen | 55111-682 | Tablet | Drugs for further processing | December 10, 2024 |
| Capecitabine | 55111-497 | Tablet | Generic drugs (ANDA) | December 10, 2020 |
| Capecitabine | 55111-496 | Tablet | Generic drugs (ANDA) | December 10, 2020 |
| Febuxostat | 55111-797 | Tablet | Generic drugs (ANDA) | November 25, 2020 |
| Febuxostat | 55111-796 | Tablet | Generic drugs (ANDA) | November 25, 2020 |
| Fexofenadine hydrochloride | 55111-783 | Tablet | Drugs for further processing | October 14, 2020 |
| Famotidine | 55111-396 | Tablet | Drugs for further processing | October 9, 2020 |
| Famotidine | 55111-118 | Tablet | Drugs for further processing | October 9, 2020 |
| Naproxen and esomeprazole magnesium | 55111-701 | Tablet, delayed release | Generic drugs (ANDA) | February 18, 2020 |
| Naproxen and esomeprazole magnesium | 55111-289 | Tablet, delayed release | Generic drugs (ANDA) | February 18, 2020 |
| Lansoprazole | 55111-739 | Capsule, delayed release | Generic drugs (ANDA) | August 19, 2019 |
| Lamotrigine | 55111-419 | Tablet, extended release | Generic drugs (ANDA) | September 6, 2018 |
| Valsartan | 55111-731 | Tablet, film coated | Generic drugs (ANDA) | March 30, 2018 |
| Palonosetron | 55111-694 | Injection, solution | Generic drugs (ANDA) | March 23, 2018 |
| Dasatinib(s)-propylene glycol | 55111-992 | Powder | Bulk ingredients | February 23, 2018 |
| Atomoxetine | 55111-564 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-563 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-528 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-522 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-521 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-520 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
| Atomoxetine | 55111-519 | Capsule | Generic drugs (ANDA) | February 23, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.